Compare KYMR & RDY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KYMR | RDY |
|---|---|---|
| Founded | 2015 | 1984 |
| Country | United States | India |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.6B | 9.9B |
| IPO Year | 2020 | 2001 |
| Metric | KYMR | RDY |
|---|---|---|
| Price | $121.83 | $12.16 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 26 | 1 |
| Target Price | ★ $107.72 | $16.90 |
| AVG Volume (30 Days) | 613.0K | ★ 2.9M |
| Earning Date | 04-30-2026 | 05-12-2026 |
| Dividend Yield | N/A | ★ 0.52% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $39,211,000.00 | N/A |
| Revenue This Year | $10.61 | $7.72 |
| Revenue Next Year | $8.17 | $3.50 |
| P/E Ratio | ★ N/A | $18.67 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $39.84 | $11.36 |
| 52 Week High | $130.05 | $15.67 |
| Indicator | KYMR | RDY |
|---|---|---|
| Relative Strength Index (RSI) | 67.81 | 43.58 |
| Support Level | $76.40 | $11.47 |
| Resistance Level | $130.05 | $12.58 |
| Average True Range (ATR) | 4.22 | 0.19 |
| MACD | 1.29 | 0.08 |
| Stochastic Oscillator | 91.57 | 60.00 |
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of differentiated medicines that address health problems and meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, and IRAK4.
Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly 40% of its generics sales, with other key markets being India (20%) and Europe (20%). Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.